Willgo SP Tablet is a combination analgesic and anti-inflammatory medication containing Aceclofenac 100 mg, Paracetamol 325 mg, and Serratiopeptidase 15 mg. Aceclofenac, a non-steroidal anti-inflammatory drug (NSAID), exerts potent anti-inflammatory, analgesic, and antipyretic effects by inhibiting cyclooxygenase enzymes, thereby reducing prostaglandin synthesis. Paracetamol contributes additional analgesic and antipyretic properties through central inhibition of prostaglandin synthesis, enhancing pain relief and fever reduction without significant anti-inflammatory action. Serratiopeptidase, a proteolytic enzyme, facilitates the breakdown of inflammatory mediators and promotes the resolution of edema and inflammation by enhancing tissue permeability and fibrinolytic activity. The synergistic combination in Willgo SP Tablet is indicated for the management of acute and chronic musculoskeletal pain, osteoarthritis, rheumatoid arthritis, postoperative pain, and soft tissue inflammatory conditions. It is effective in reducing pain, swelling, and inflammation, thereby improving patient mobility and quality of life. Caution is advised in patients with gastrointestinal ulcers, hepatic or renal impairment, and hypersensitivity to NSAIDs. The medication should be used under medical supervision, adhering to prescribed dosages to minimize adverse effects such as gastrointestinal discomfort, allergic reactions, or potential bleeding risks associated with NSAID use.